{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:17:31Z","timestamp":1791065851954,"version":"4.1.0"},"reference-count":0,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2002,10,22]],"date-time":"2002-10-22T00:00:00Z","timestamp":1035244800000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2002,10]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Combination therapy of ribavirin with interferon alfa\u20102b and pegylated interferon alfa\u20102b is currently approved for the treatment of chronic hepatitis C. Approved ribavirin dosages vary from a fixed dosage of 800 mg\/d to as much as 1200 mg\/d on the basis of body weight.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>Our objective was to evaluate ribavirin dosing strategies by comparison of their relative efficacy and toxicity profiles.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Three models were developed on the basis of data collected from a large phase III trial. A population pharmacokinetic model was used to describe the ribavirin dose\u2010concentration relationship and the influence of covariates. Logistic regression models were developed for both sustained virologic response and hematologic toxicity. Ribavirin concentration was an important explanatory variable for both response and toxicity. Simulations of these models were developed for different ribavirin doses to obtain efficacy and toxicity profiles across the various dosing strategies. These strategies included a fixed 800\u2010mg\/d dose, empiric weight\u2010adjusted doses (ie, 1000 mg\/d for patients who weighed \u226475 kg and 1200 mg\/d for patients who weighed &gt;75 kg [1000\/1200 mg\/d on the basis of body weights \u226475\/&gt;75 kg] and 800 mg\/d for patients who weighed &lt;65 kg, 1000 mg\/d for patients who weighed from 65 to 85 kg, and 1200 mg\/d for patients who weighed &gt;85 kg [800\/1000\/1200 mg\/d on the basis of body weights &lt;65\/65\u201085\/&gt;85 kg]), a dose of 13 mg\/kg per day, and other per\u2010body weight doses between 9 and 16 mg\/kg per day.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Simulation results showed that both efficacy and toxicity increased as the milligrams\u2010per\u2010kilogram dose of ribavirin increased. The body weight\u2010based 800\/1000\/1200\u2010mg\/d dose had overall response and toxicity rates that were 6.3% and 2.5% higher than those of the fixed 800\u2010mg\/d dose. In particular, patients with genotype\u20101 disease had a 7.4% increase in response rate. There were no differences in response and toxicity rates between the 800\/1000\/1200\u2010mg\/d and 13\u2010mg\/kg per day dose groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This simulation suggests that ribavirin dosage (in combination with pegylated interferon alfa\u20102b) for patients with chronic hepatitis C should be based on body weight.<\/jats:p><jats:p><jats:italic>Clinical Pharmacology &amp; Therapeutics<\/jats:italic> (2002) <jats:bold>72<\/jats:bold>, 349\u2013361; doi: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"doi\" xlink:href=\"10.1067\/mcp.2002.127112\">10.1067\/mcp.2002.127112<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1067\/mcp.2002.127112","type":"journal-article","created":{"date-parts":[[2002,11,5]],"date-time":"2002-11-05T13:49:19Z","timestamp":1036504159000},"page":"349-361","source":"Crossref","is-referenced-by-count":49,"title":["Ribavirin dosing in chronic hepatitis C: Application of population pharmacokinetic\u2010pharmacodynamic models"],"prefix":"10.1111","volume":"72","author":[{"given":"Juif","family":"Jen","sequence":"first","affiliation":[{"name":"Departments of Statistics, Clinical Pharmacology, and Drug Metabolism\/Pharmacokinetics, Schering\u2010Plough Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Laughlin","sequence":"additional","affiliation":[{"name":"Departments of Statistics, Clinical Pharmacology, and Drug Metabolism\/Pharmacokinetics, Schering\u2010Plough Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Chung","sequence":"additional","affiliation":[{"name":"Departments of Statistics, Clinical Pharmacology, and Drug Metabolism\/Pharmacokinetics, Schering\u2010Plough Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Heft","sequence":"additional","affiliation":[{"name":"Departments of Statistics, Clinical Pharmacology, and Drug Metabolism\/Pharmacokinetics, Schering\u2010Plough Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melton B.","family":"Affrime","sequence":"additional","affiliation":[{"name":"Departments of Statistics, Clinical Pharmacology, and Drug Metabolism\/Pharmacokinetics, Schering\u2010Plough Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir K.","family":"Gupta","sequence":"additional","affiliation":[{"name":"Departments of Statistics, Clinical Pharmacology, and Drug Metabolism\/Pharmacokinetics, Schering\u2010Plough Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Glue","sequence":"additional","affiliation":[{"name":"Departments of Statistics, Clinical Pharmacology, and Drug Metabolism\/Pharmacokinetics, Schering\u2010Plough Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Hajian","sequence":"additional","affiliation":[{"name":"Departments of Statistics, Clinical Pharmacology, and Drug Metabolism\/Pharmacokinetics, Schering\u2010Plough Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,10,22]]},"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1067\/mcp.2002.127112","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T10:03:47Z","timestamp":1700301827000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1067\/mcp.2002.127112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10]]},"references-count":0,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,10]]}},"alternative-id":["10.1067\/mcp.2002.127112"],"URL":"https:\/\/doi.org\/10.1067\/mcp.2002.127112","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,10]]}}}